Developer docs
API playgroundTry for free, no card

Search company profiles

Codebreaker Labs

Full company profile

uuid02mimv8

Namestring
Codebreaker Labs
Legal namestring
Codebreaker Labs
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Codebreaker Labs is a Boulder, Colorado-based private biotechnology company founded in 2025 that builds causal genomics data by experimentally mapping genetic variants to cellular effects. The company combines high-throughput DNA synthesis, next-generation CRISPR technologies (including the proprietary MAD7, Onyx, and STAR-CRISPR platforms pioneered by the founding team) and single-cell assays to generate the Codex of Variant Profiles, a continuously expanding dataset of experimentally validated variant effects on human cell behavior built from tens of thousands of parallel-programmed variants and tens of millions of single-cell phenotypic fingerprints.

The company operates a platform-plus-modules architecture. The core asset is the Codex of Variant Profiles, which serves as training and ground-truthing data for the company's AI. Layered on top is Arlington AI, a clinical decision support system that integrates patient WGS/WES data with the Codex and proprietary predictive AI to interpret variants of unknown significance by placing them in context of biologically validated neighbors. The product suite also includes the BioData-as-a-Service Platform for custom variant mapping and a prototype Data Explorer visualization interface, with the INSIGHTS analytical module listed as forthcoming.

Codebreaker generates revenue through subscription/recurring enterprise relationships. The Codex Pioneers Program, an invitation-based channel, targets leading hospitals with early access to Arlington AI and the Codex, priority support, pilot access, and co-publication rights. Biopharma partners access custom variant mapping through the BioData-as-a-Service Platform. Pricing is not publicly disclosed and is structured through bespoke collaboration agreements. The company has raised approximately $4.48M in a single funding round on 2026-08-26 and operates with 1-10 employees.

Short descriptiontext

Codebreaker Labs is a Boulder-based biotech founded in 2025 that builds causal genomics data by experimentally mapping genetic variants to cellular effects. It sells the Codex of Variant Profiles dataset, Arlington AI clinical decision support, and custom variant-mapping services to hospitals and biopharma partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoulder, United States
HQ citystring
Boulder
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
causal genomics, variant interpretation, clinical decision support, functional genomics data, genomic data platform
Industry4 codes
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genomics Software
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1BioData-as-a-Service Platform
TypeSubscription Recurring
Description

Custom variant mapping collaborations providing access to proprietary causal genomics data and experimental capabilities for biopharma and research partners.

codebreakerlabs.io
2Arlington AI Clinical Decision Support Software
TypeSubscription Recurring
Description

Clinical decision support system for WGS and WES interpretation, enabling faster and more accurate rare variant case analysis for healthcare providers.

codebreakerlabs.io
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 4 records shown
1Arlington AI
Description

Clinical Decision Support Software system that integrates patient genomic data with Codex of Variant Profiles and proprietary predictive AI for faster, more accurate interpretation of rare and challenging cases.

codebreakerlabs.io
+3 more records
Core offering1 text field

Codebreaker Labs builds causal genomics data by experimentally mapping genetic variants to cellular effects at scale, using high-throughput DNA synthesis, next-generation CRISPR technologies, and single-cell assays. The company sells the Codex of Variant Profiles, a continuously expanding dataset of experimentally validated variant effects, the Arlington AI clinical decision support software for rare variant interpretation, and a bioData-as-a-Service platform for custom variant mapping collaborations with biopharma partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Reduces interpretation time from months/years to faster clinical insights for rare and challenging genomic cases
Product overview1 text field

Codebreaker Labs offers a platform-plus-modules architecture centered on its proprietary Codex of Variant Profiles—the world's largest dataset of causal variant effects on human cell behavior. The core platform combines bioData-as-a-Service for custom variant mapping collaborations with Arlington AI, a clinical decision support software that integrates patient genomic data with the Codex and predictive AI for variant interpretation. The Arlington AI suite includes the main CDS software and the forthcoming INSIGHTS module, with a Data Explorer prototype feature demonstrating visualization capabilities.

Product and service3 records
1Codex of Variant Profiles
CategoryGenomics Data Platform
Description

A continuously expanding library of experimentally validated variant effects on human cell behavior, generated through high-throughput DNA synthesis and single-cell assays. The dataset serves as the foundational resource for training and ground-truthing AI models for variant interpretation.

2Arlington AI Clinical Decision Support Software
CategoryClinical Decision Support Software
Description

A next-generation clinical decision support system that integrates patient genomic data (WGS/WES) with the Codex of Variant Profiles and proprietary predictive AI to enable faster, more accurate interpretation of rare and challenging clinical cases, including variants that elude expert review.

3bioData-as-a-Service Platform
CategoryCustom Research Services
Description

Custom variant mapping collaborations enabling partners to leverage Codebreaker's synthetic biology platform for generating proprietary variant effect data tailored to specific research or clinical needs.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Codex Pioneers Partner Hospitals
Strategic tierCoreTypeStrategic or Co-development Partner
Description

The Codex Pioneers Program invites leading hospitals to partner with Codebreaker for early access to the Arlington AI platform and Codex of Variant Profiles. Partners gain the opportunity to nominate high-priority variants for functional mapping, receive priority support and pilot access, and participate in co-publications. This represents a strategic co-development relationship focused on transforming genomic uncertainty into clinical clarity.

codebreakerlabs.io
2Biopharma Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Codebreaker has established successful collaborations with leading biopharma partners through Artisan Biosciences, including a five-year period of productive partnerships. These collaborations focus on custom variant mapping and biological ground truth data generation for therapeutic development applications.

codebreakerlabs.io
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Co-founded by CEO Ryan T. Gill, Inscripta developed commercial-scale CRISPR-based genome engineering platforms (including the Onyx platform). It is the most direct technology ancestor to Codebreaker's Codex pipeline and shares the same founders and core wet-lab approach.

2Artisan Biosciences
TypeDirect peer
Description

Also co-founded by Gill and Warnecke-Gill, Artisan operated a five-year biopharma services business doing custom genome-engineering collaborations. Codebreaker's BioData-as-a-Service Platform is effectively an extension of Artisan's biopharma services model applied to functional variant mapping.

TypeDirect peer
Description

AI-driven company focused on identifying novel therapeutic targets and interpreting genetic variation for drug discovery. Directly comparable as an AI-for-genomics platform competing for biopharma R&D budgets and emphasizing computational interpretation of variants.

TypeBroad incumbent
Description

Large-scale AI-for-biology platform combining high-throughput experimental data generation with machine learning. Comparable in spirit (wet-lab + AI loop generating proprietary biological data) but operates at much larger scale across broader indication areas rather than focusing specifically on variant interpretation.

TypeBroad incumbent
Description

Machine learning-driven drug discovery company that generates proprietary experimental datasets (e.g., induced pluripotent stem cell-derived data) to train models. Shares the 'generate biological ground truth data to train AI' philosophy, though focused on phenotypic screens for therapeutics rather than variant effects.

6Tempus Labs
TypeBroad incumbent
Description

Established leader in clinical genomics and AI-driven precision medicine, offering NGS testing and clinical decision support tools to hospitals and oncologists. Directly comparable as a buyer of hospital clinical genomics interpretation capacity and as a competitor in CDS software for variant analysis.

TypeBroad incumbent
Description

Major clinical genomics company (Roche subsidiary) providing comprehensive genomic profiling and clinical decision support for oncology. Comparable as a hospital-facing platform that interprets variants at scale and could either compete with or partner around Arlington AI.

TypeBroad incumbent
Description

Clinical genetic testing company providing WES/WGS and variant interpretation services to clinicians. Overlaps with Codebreaker's hospital customer base and competes for the same clinical genomics interpretation budget.

TypeEmerging player
Description

AI-for-healthcare company building models on multimodal patient and biological data, including genomic data, with biopharma and hospital customers. Comparable as an emerging AI-for-clinical-genomics player with a similar biopharma + hospital dual GTM.

10Function Biosciences
TypeEmerging player
Description

Emerging functional genomics company using high-throughput experimental assays to map variant function at scale, often targeting biopharma partners. Direct overlap in 'wet-lab functional genomics at scale for AI training data' thesis, though at an earlier stage and smaller scale than Codebreaker's claimed Codex pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Codebreaker Labs

Genomics Softwarecodebreakerlabs.io

Codebreaker Labs is a Boulder-based biotech founded in 2025 that builds causal genomics data by experimentally mapping genetic variants to cellular effects. It sells the Codex of Variant Profiles dataset, Arlington AI clinical decision support, and custom variant-mapping services to hospitals and biopharma partners.

What Codebreaker Labs does

Codebreaker Labs is a Boulder, Colorado-based private biotechnology company founded in 2025 that builds causal genomics data by experimentally mapping genetic variants to cellular effects. The company combines high-throughput DNA synthesis, next-generation CRISPR technologies (including the proprietary MAD7, Onyx, and STAR-CRISPR platforms pioneered by the founding team) and single-cell assays to generate the Codex of Variant Profiles, a continuously expanding dataset of experimentally validated variant effects on human cell behavior built from tens of thousands of parallel-programmed variants and tens of millions of single-cell phenotypic fingerprints.

The company operates a platform-plus-modules architecture. The core asset is the Codex of Variant Profiles, which serves as training and ground-truthing data for the company's AI. Layered on top is Arlington AI, a clinical decision support system that integrates patient WGS/WES data with the Codex and proprietary predictive AI to interpret variants of unknown significance by placing them in context of biologically validated neighbors. The product suite also includes the BioData-as-a-Service Platform for custom variant mapping and a prototype Data Explorer visualization interface, with the INSIGHTS analytical module listed as forthcoming.

Codebreaker generates revenue through subscription/recurring enterprise relationships. The Codex Pioneers Program, an invitation-based channel, targets leading hospitals with early access to Arlington AI and the Codex, priority support, pilot access, and co-publication rights. Biopharma partners access custom variant mapping through the BioData-as-a-Service Platform. Pricing is not publicly disclosed and is structured through bespoke collaboration agreements. The company has raised approximately $4.48M in a single funding round on 2026-08-26 and operates with 1-10 employees.

Codebreaker Labs firmographics

Firmographics
Name
Codebreaker Labs
Legal name
Codebreaker Labs
Website
https://codebreakerlabs.io
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Codebreaker Labs is a Boulder-based biotech founded in 2025 that builds causal genomics data by experimentally mapping genetic variants to cellular effects. It sells the Codex of Variant Profiles dataset, Arlington AI clinical decision support, and custom variant-mapping services to hospitals and biopharma partners.
Ownership category
akta.pro rank

Codebreaker Labs industry classification

Industry
Product category
Genomics Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAG
CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Causal genomics
  • Variant interpretation
  • Clinical decision support
  • Functional genomics data
  • Genomic data platform

Where Codebreaker Labs is headquartered

Location

Headquarters

HQ city
Boulder
HQ country
United States
HQ region
North America

Markets served

Codebreaker Labs business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. BioData-as-a-Service Platform: Custom variant mapping collaborations providing access to proprietary causal genomics data and experimental capabilities for biopharma and research partners.
  2. Arlington AI Clinical Decision Support Software: Clinical decision support system for WGS and WES interpretation, enabling faster and more accurate rare variant case analysis for healthcare providers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Codebreaker Labs product offering

Product offering

Core offering

Codebreaker Labs builds causal genomics data by experimentally mapping genetic variants to cellular effects at scale, using high-throughput DNA synthesis, next-generation CRISPR technologies, and single-cell assays. The company sells the Codex of Variant Profiles, a continuously expanding dataset of experimentally validated variant effects, the Arlington AI clinical decision support software for rare variant interpretation, and a bioData-as-a-Service platform for custom variant mapping collaborations with biopharma partners.

Product overview

Codebreaker Labs offers a platform-plus-modules architecture centered on its proprietary Codex of Variant Profiles—the world's largest dataset of causal variant effects on human cell behavior. The core platform combines bioData-as-a-Service for custom variant mapping collaborations with Arlington AI, a clinical decision support software that integrates patient genomic data with the Codex and predictive AI for variant interpretation. The Arlington AI suite includes the main CDS software and the forthcoming INSIGHTS module, with a Data Explorer prototype feature demonstrating visualization capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Arlington AI: Clinical Decision Support Software system that integrates patient genomic data with Codex of Variant Profiles and proprietary predictive AI for faster, more accurate interpretation of rare and challenging cases.
  • Codex of Variant Profiles
  • bioData-as-a-Service Platform
  • Codex Pioneers Program

Products and services

  • Codex of Variant Profiles A continuously expanding library of experimentally validated variant effects on human cell behavior, generated through high-throughput DNA synthesis and single-cell assays. The dataset serves as the foundational resource for training and ground-truthing AI models for variant interpretation.
  • Arlington AI Clinical Decision Support Software A next-generation clinical decision support system that integrates patient genomic data (WGS/WES) with the Codex of Variant Profiles and proprietary predictive AI to enable faster, more accurate interpretation of rare and challenging clinical cases, including variants that elude expert review.
  • bioData-as-a-Service Platform Custom variant mapping collaborations enabling partners to leverage Codebreaker's synthetic biology platform for generating proprietary variant effect data tailored to specific research or clinical needs.

Quantifiable outcome

  • Reduces interpretation time from months/years to faster clinical insights for rare and challenging genomic cases

Companies that use Codebreaker Labs

Customer profile

Segments2 records

Ideal customer profiles2 records

Codebreaker Labs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Codebreaker Labs partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Codex Pioneers Partner HospitalscoreStrategic or Co-development PartnerThe Codex Pioneers Program invites leading hospitals to partner with Codebreaker for early access to the Arlington AI platform and Codex of Variant Profiles. Partners gain the opportunity to nominate high-priority variants for functional mapping, receive priority support and pilot access, and participate in co-publications. This represents a strategic co-development relationship focused on transforming genomic uncertainty into clinical clarity.
  • Biopharma PartnerscoreStrategic or Co-development PartnerCodebreaker has established successful collaborations with leading biopharma partners through Artisan Biosciences, including a five-year period of productive partnerships. These collaborations focus on custom variant mapping and biological ground truth data generation for therapeutic development applications.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Codebreaker Labs competitors and assessment

Company assessment

Direct peers

  • Inscripta: Co-founded by CEO Ryan T. Gill, Inscripta developed commercial-scale CRISPR-based genome engineering platforms (including the Onyx platform). It is the most direct technology ancestor to Codebreaker's Codex pipeline and shares the same founders and core wet-lab approach.
  • Artisan Biosciences: Also co-founded by Gill and Warnecke-Gill, Artisan operated a five-year biopharma services business doing custom genome-engineering collaborations. Codebreaker's BioData-as-a-Service Platform is effectively an extension of Artisan's biopharma services model applied to functional variant mapping.
  • Deep Genomics: AI-driven company focused on identifying novel therapeutic targets and interpreting genetic variation for drug discovery. Directly comparable as an AI-for-genomics platform competing for biopharma R&D budgets and emphasizing computational interpretation of variants.

Broad incumbents

  • Recursion Pharmaceuticals: Large-scale AI-for-biology platform combining high-throughput experimental data generation with machine learning. Comparable in spirit (wet-lab + AI loop generating proprietary biological data) but operates at much larger scale across broader indication areas rather than focusing specifically on variant interpretation.
  • Insitro: Machine learning-driven drug discovery company that generates proprietary experimental datasets (e.g., induced pluripotent stem cell-derived data) to train models. Shares the 'generate biological ground truth data to train AI' philosophy, though focused on phenotypic screens for therapeutics rather than variant effects.
  • Tempus Labs: Established leader in clinical genomics and AI-driven precision medicine, offering NGS testing and clinical decision support tools to hospitals and oncologists. Directly comparable as a buyer of hospital clinical genomics interpretation capacity and as a competitor in CDS software for variant analysis.
  • Foundation Medicine: Major clinical genomics company (Roche subsidiary) providing comprehensive genomic profiling and clinical decision support for oncology. Comparable as a hospital-facing platform that interprets variants at scale and could either compete with or partner around Arlington AI.
  • Invitae: Clinical genetic testing company providing WES/WGS and variant interpretation services to clinicians. Overlaps with Codebreaker's hospital customer base and competes for the same clinical genomics interpretation budget.

Emerging players

  • Owkin: AI-for-healthcare company building models on multimodal patient and biological data, including genomic data, with biopharma and hospital customers. Comparable as an emerging AI-for-clinical-genomics player with a similar biopharma + hospital dual GTM.
  • Function Biosciences: Emerging functional genomics company using high-throughput experimental assays to map variant function at scale, often targeting biopharma partners. Direct overlap in 'wet-lab functional genomics at scale for AI training data' thesis, though at an earlier stage and smaller scale than Codebreaker's claimed Codex pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Codebreaker Labs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Codebreaker Labs leadership team

Management profile

Number of profiles

Profiles3 records

Codebreaker Labs funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Codebreaker Labs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Codebreaker Labs

What does Codebreaker Labs do?

Codebreaker Labs builds causal genomics data by experimentally mapping genetic variants to cellular effects at scale, using high-throughput DNA synthesis, next-generation CRISPR technologies, and single-cell assays. The company sells the Codex of Variant Profiles, a continuously expanding dataset of experimentally validated variant effects, the Arlington AI clinical decision support software for rare variant interpretation, and a bioData-as-a-Service platform for custom variant mapping collaborations with biopharma partners.

Is Codebreaker Labs a public or private company?

Codebreaker Labs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Codebreaker Labs founded?

Codebreaker Labs was founded in 2025. It employs 1 to 10 people.

Where is Codebreaker Labs based?

Codebreaker Labs is headquartered in Boulder, United States, in the North America region.

How does Codebreaker Labs make money?

Two revenue lines are on record. BioData-as-a-Service Platform is the primary driver. The others are arlington AI Clinical Decision Support Software.

Who are Codebreaker Labs's main competitors?

Direct peers on record are Inscripta, Artisan Biosciences and Deep Genomics. Broad incumbents are Recursion Pharmaceuticals, Insitro, Tempus Labs, Foundation Medicine and Invitae. Emerging players are Owkin and Function Biosciences.

Does Codebreaker Labs have an API?

No public API is recorded for Codebreaker Labs.

What industry is Codebreaker Labs in?

Codebreaker Labs's product category is Genomics Software. Its primary akta.pro industry code is HLAAAIAG, CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq), with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireParse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at ScaleParse Biosciences and Codebreaker Labs announced a collaboration to develop a platform that tests thousands of genetic variants in parallel and measures their effects at single-cell resolution. The platform combines Codebreaker's synthetic biology with Parse's Evercode technology to generate causal data for rare variants. The collaboration aims to benefit biopharma, precision medicine, and AI development.The SaaS NewsCodebreaker Labs Raises $4.5M SeedCodebreaker Labs raised $4.5 million in seed funding led by Kickstart. The genomic AI company will use the capital to scale laboratory operations, hire scientific personnel, and develop its first variant Atlases and AI-powered interpretation tools.GlobalfintechseriesCodebreaker Labs Raises Seed Round to Scale First-of-Its-Kind Data for Genomic AICodebreaker Labs closed a $4.5 million seed round led by Kickstart to scale its genomic AI platform. The funding will support laboratory scale-up, scientific hires, and development of its first Atlas, targeting 100,000 variants, with a commercial Atlas expected in 2027.EIN PresswireCodebreaker Labs Raises Seed Round to Scale First-of-Its-Kind Data for Genomic AICodebreaker Labs raised a $4.5 million seed round led by Kickstart to scale its genomic AI platform. The company will develop its first Atlas, measuring effects of 100,000 genomic variants, with a commercial Atlas targeted for 2027.citybizCodebreaker Labs Raises $4.5M Seed Round to Scale Genomic AI DataCodebreaker Labs raised $4.5 million in a seed round led by Kickstart to scale its genomic AI data platform. The Colorado-based company will use the funds to expand lab operations, hire scientists, and develop variant Atlases and AI tools. Its first Atlas, targeting 100,000 variants, is planned for 2027.RuntimewireCodebreaker Labs files first Form D, leaves offering amount undisclosedCodebreaker Labs filed its first SEC Form D on August 26, disclosing a financing effort to manufacture experimental data on genetic variants in living cells. The filing does not quantify the offering or identify investors. The company plans to use the data to improve genomics AI models.